omics technologies

What omics technologies does

Omics Technologies Inc. is a privately held Contract Research Organization (CRO) headquartered at 6700 Alexander Bell Drive, STE 200-A, Columbia, Maryland, that delivers specialized proteomics and genomics research services to pharmaceutical companies, biotechnology firms, and academic research institutions. The company's portfolio is organized around two core service lines: Proteomics Services (proteomics.omicstech.com), built around patented targeted proteomics plus qualitative and quantitative protein analysis, and Genomics Services (genomics.omicstech.com), built on Next-Generation Sequencing (NGS) workflows capable of accepting any biological sample type. The company states that its methodologies — including targeted proteomics and NGS — are patented, and that it can process samples from any biological source, framing itself as a personalized-healthcare-oriented research partner.

The commercial model is professional-services based: clients engage Omics Technologies on a contract, project-by-project basis for specialized analytical work. Go-to-market is sales-led and executed through direct outreach via phone (+1 888-206-0066), email ([email protected]), and a website inquiry form, with no channel partners or self-service commerce evident. Target use cases span drug discovery, biomarker identification, disease mechanism studies, and personalized healthcare research, with primary customer segments split between pharmaceutical companies and biotechnology firms, supplemented by academic and institutional research organizations. Pricing is handled on a per-engagement basis and is not publicly disclosed.

The organization is small and opaque in its public footprint. No headcount, revenue, funding history, named customer logos, leadership bios, partnership agreements, regulatory actions, or product launch dates are disclosed in the available source material. Marketing activity is constrained to the company website and direct contact channels, with no observable social media, content marketing, paid acquisition, or ecosystem programs. A 2019 copyright notice on the corporate website is the only concrete indicator of operational longevity.

Name

omics technologies

Legal name

Omics Technologies Inc.

Website

https://omicstech.com

Company type

Private

Operating status

Operating

Short description

Omics Technologies is a privately held Contract Research Organization providing patented proteomics and genomics (NGS) research services to pharmaceutical, biotechnology, and academic clients via a sales-led professional services model from Columbia, Maryland.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

Keywords

• Proteomics research services
• Genomics sequencing services
• Contract research organization
• Biomarker discovery services
• Drug discovery support

Headquarters

HQ city

Columbia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Omics Technologies operates as a Contract Research Organization (CRO) providing specialized proteomics and genomics research services to pharmaceutical companies, biotechnology firms, and research institutions on a contractual basis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Omics Technologies is a Contract Research Organization (CRO) that provides proteomics and genomics research services to pharmaceutical companies, biotechnology firms, and research institutions. Its core offerings include targeted proteomics, qualitative and quantitative proteomics, and Next-Generation Sequencing (NGS) genomics analysis, all backed by the company's patented technologies and capable of processing samples from any biological source.

Product overview

Omics Technologies operates as a Contract Research Organization (CRO) offering two core service lines: Proteomics Services and Genomics Services. The company provides state-of-the-art proteomics research including targeted proteomics and qualitative and quantitative proteomics, as well as genomics NGS services. All services utilize the company's patented technologies and can process samples from any biological source. The product portfolio consists of these two integrated service offerings accessible through separate subdomains.

Differentiator

Problem solved

Functional benefit

Products and services

• Proteomics Services

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves2 records

Direct peers

• Biognosys: Biognosys is a Switzerland-based specialty CRO offering targeted and quantitative proteomics services using patented workflows such as parallel reaction monitoring (PRM). It is the closest direct peer to Omics Technologies' targeted proteomics offering and serves the same pharma and biotech drug-discovery customers.
• Cell Signaling Technology (CST): CST operates a commercial proteomics services arm (CST Proteomics) that performs quantitative phosphoproteomics and targeted protein analysis for pharmaceutical and academic clients. The service portfolio closely mirrors Omics Technologies' targeted and quantitative proteomics capabilities and serves an identical customer base.
• Active Motif: Active Motif offers both proteomics and genomics (NGS-based ChIP-seq, ATAC-seq, RNA-seq) services from biological samples for academic and pharma research customers. Its dual-omics service mix and B2B CRO model make it a tight comparable to Omics Technologies' combined proteomics and genomics offering.
• Azenta Life Sciences (formerly GENEWIZ): Azenta provides genomics services including NGS, Sanger sequencing, and increasingly multi-omics through its GENEWIZ and Biorepository units. It is a direct competitor in Omics Technologies' genomics NGS line and similarly sells into pharma, biotech, and academic customers.

Emerging players

• Olink Holding: Olink provides a proprietary high-throughput proteomics platform (Proximity Extension Assay) increasingly used by pharma biomarker programs and is expanding into proteomics service offerings. While more product-platform than pure CRO, it competes for the same targeted proteomics budget as Omics Technologies and validates the precision-medicine proteomics thesis.
• SomaLogic (now part of Standard BioTools): SomaLogic operates the SomaScan platform for large-scale proteomic profiling, serving pharma biomarker discovery and personalized healthcare research. Its biomarker-focused commercial proteomics offering competes with Omics Technologies' targeted and quantitative proteomics services for the same pharmaceutical R&D use cases.

Broad incumbents

• NeoGenomics Laboratories: NeoGenomics is a publicly traded clinical and research genomics services company with CLIA-certified labs and an extensive oncology-focused NGS menu. It competes in the same pharma/biotech genomics services market as Omics Technologies with substantially greater scale, certifications, and enterprise relationships.
• Eurofins Scientific: Eurofins operates a global network of laboratories offering both proteomics and genomics services to pharma, biotech, and academic customers. It is a broad incumbent competitor with significant scale advantages, multiple accreditations, and integrated bioinformatic pipelines that Omics Technologies would have to differentiate against.

Regional players

• BGI Genomics: BGI Genomics is a leading Asia-based genomics services provider with global NGS, sequencing, and proteomics offerings serving pharma and academic customers. It competes with Omics Technologies in the genomics NGS line and offers a comparable sample-agnostic service model, though its primary geographic footprint is Asia.
• MedGenome: MedGenome is an India- and US-based genomics and multi-omics services company serving pharma, biotech, and research institutions with NGS, exome, and increasingly proteomics capabilities. It is comparable to Omics Technologies' combined genomics and proteomics CRO model and targets the same drug-discovery and biomarker research use cases.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about omics technologies